It has been a major week in the stem cell industry, with partnerships, licensing deals, and pre-clinical findings recently announced. Check out the latest coverage below. [Read more…]
BrainXell Enters Agreement for iPSC Patent Technology with iPS Academia Japan
BrainXell and iPS Academia Japan have announced a global licensing agreement covering components of the induced pluripotent stem (iPS) cell patent portfolio owned by iPS Academia Japan. Under the terms of the non-exclusive agreement, BrainXell will be able to commercialize iPS-derived cells and offer related services to it customers. The value and terms of the agreement have not been announced.
The iPS cell patent portfolio being licensed by BrainXell has resulted from work by Professor Shinya Yamanaka at the Center for iPS Cell Research and Application (CiRA) at Kyoto University.
BrainXell is a a stem cell company based in Madison, Wisconsin, while iPS Academia Japan is based in Kyoto, Japan. BrainXell specializes in using iPSC-derived neural cells for use on a custom basis to pharmaceutical companies for research programs. iPS Academia Japan is an affiliate of Kyoto University, a major research university in Japan. Kyoto University is also a global leader in developing induced pluripotent stem cell (iPSC) technologies.
BrainXell is making brain cells by the billions. @UWMadison spinoff sells neural cells to drug researchers via @UWMadScience. pic.twitter.com/zuw6l0EMec
— CIRM (@CIRMnews) November 1, 2016
The role of iPS Acadmia Japan is to commercialize the patents and other IP created by Kyoto University and other universities and research institutions developing iPSC technologies.
According to Zhong-Wei Du, Chief Technology Officer of BrainXell, “BrainXell is now enabled through this iPS cell technology license and its Wisconsin Alumni Research Foundation (WARF) license on neural stem cell differentiation to provide a broad range of neural cells for research at numerous institutions and biopharmaceutical companies.”
To learn more, view the license announcement.
Cynata and FUJIFILM Sign Non-binding Development and Commercialisation Term Sheet
Melbourne, Australia; 5 September 2016 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced the execution of a term sheet with FUJIFILM Corporation of Japan for the development and commercialisation of certain Cynata technology, including Cynata’s lead induced pluripotent stem cell (iPSC) derived therapeutic mesenchymal stem cell (MSC) product, CYP-001. Pursuant to the term sheet, the parties will work together to seek to finalise a definitive agreement. If the parties enter into a definitive agreement, Cynata expects it to be finalised in the fourth quarter of 2016. [Read more…]
Cynata Shares Jump as Japan’s FUJIFILM Negotiates Deal to Commercialize Cymerus™ Stem Cell Technology
Cynata Therapeutics (ASX: CYP) has executed a term sheet with FUJIFILM Corporation of Japan for the development and commercialisation of certain Cynata technology, including Cynata’s lead product, CYP-001. CYP-001 is an induced pluripotent stem cell (iPSC) derived mesenchymal stem cell (MSC) product that is anticipated to be the first allogeneic iPSC product to enter a clinical trial.
European Society of Cardiology (ESC) Congress Presentation Reveals Results From Pre-Clinical Study Using CardioCell’s Stem Cells for Acute Myocardial Infarction
Data Indicate Administering Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) Intravenously Improves Cardiac Function Following an AMI
ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 29, 2016 – Study sponsor CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces data from its pre-clinical study “Mesenchymal stem cells grown under chronic hypoxia traffic to regions of myocardial infarction, suppress splenic natural killer cells, and attenuate adverse remodeling in mice with large acute MI” at the European Society of Cardiology (ESC) Congress.
Paper Co-Author Dr. Michael Lipinski, Interventional Cardiologist at MedStar Washington Hospital Center, presents the study that was designed in collaboration with Drs. Dror Luger, Research Scientist at Washington Hospital Center and Stephen Epstein, Director, Translational and Vascular Biology Research at MedStar Heart and Vascular Institute, Chair of CardioCell’s Scientific Advisory Board and Member of CardioCell’s Heart Failure Advisory Board. [Read more…]
- « Previous Page
- 1
- …
- 280
- 281
- 282
- 283
- 284
- …
- 334
- Next Page »